Inovio » About Us » Leadership » Biography

"Vaccines are among the greatest achievements of biomedical science and public health, stimulating protective immune responses against acute and chronic infectious diseases, as well as some infectious diseases that result in cancer."

Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States
Journal of the American Medical Association
November, 2007

"I have stated in public seminars that, in my opinion, electroporation is the gold standard for DNA vaccine delivery, giving us the best result in terms of immunogenicity of DNA vaccines."

George N. Pavlakis, MD, PhD
Chief
Human Retrovirus Section, Vaccine Branch
National Cancer Institute

home » about us » leadership » j. joseph kim

Biography

J. Joseph Kim, Ph.D.
President, Chief Executive Officer, Director

JOSEPH KIM became the CEO of Inovio Biomedical with the completion of the company’s merger with VGX Pharmaceuticals in June 2009. Dr. Kim co-founded VGX in December 2000 as a start-up based on technology licensed from the University of Pennsylvania and was VGX’s CEO. Previously, Dr. Kim led efforts in manufacturing and process development of several FDA-approved products and developmental therapeutics at Merck & Co. These products include FDA-approved vaccines for hepatitis as well as developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim has published over 70 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels.

Dr. Kim has a B.Sc. in Chemical Engineering and Economics from MIT, where he was a U.S. Senate Honors Scholar. He holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.

Dr. Kim has recognized with numerous honors during his career:

2002: MIT's Technology Review, one of the world's Top 100 Young Innovators
2002: Philadelphia Business Journal, one of "40 under 40" dynamic professionals
2003 and 2006: Details Magazine, selected as one of "50 Most Influential Men"
2004: World Economic Forum, selection of Dr. Kim and VGX Pharmaceuticals as one of 30 Technology Pioneers
2005: Newsweek International, profiled in annual "Who's Next" issue as one of 10 leaders, scientists, and executives at the forefront of change and impact in the world
2006: Forum of Young Global Leaders, an affiliate of the World Economic Forum, named a Young Global Leader among 175 leading executives, public figures and intellectuals under the age of 40 from 50 countries.